![pageSearch](/themes/hestia/images/page-search.png)
2023 Husqvarna FE 450 Test
Aug 02, 2023Forget Shardul V Ashwin, Umesh Over Undakat Is The Selection Slip That Could Decide The WTC Final
Sep 10, 2023Nissan Altima Lower Control Arm Replacement Program
Dec 18, 2023Performance Driving Is Possible for Drivers with Disabilities
Jan 03, 2024Sealed Units Matter (VIDEO)
May 14, 2023RIST Improves PFS in Relapsed/Refractory Neuroblastoma
![Dec 10, 2023](/themes/hestia/images/news-details-icon1.png)
Combination treatment with rapamycin, dasatinib, irinotecan, and temozolomide (RIST) improves progression-free survival (PFS) in children and young adults with relapsed or refractory neuroblastoma, when compared to irinotecan plus temozolomide, a phase 2 study suggests.
In the entire study cohort, there was no improvement in overall survival (OS) with RIST. However, RIST did improve OS among patients with MYCN-amplified disease.
These results were presented at the ASCO Annual Meeting 2023 by Selim Corbacioglu, MD, PhD, of University Hospital of Regensburg in Germany.
The phase 2 RIST-rNB-2011 study (ClinicalTrials.gov Identifier: NCT01467986) enrolled patients aged 25 years or younger with relapsed or refractory, stage IV neuroblastoma, 39% of whom had MYCN-amplified disease. The efficacy population included 124 patients who were randomly assigned to receive RIST (n=61) or irinotecan and temozolomide (n=63).
At a median follow-up of 72 months, the median PFS was significantly longer for patients in the RIST arm than those in the control arm — 11 months and 5 months, respectively (hazard ratio [HR], 0.62; 95% CI, 0.42-0.92; P =.019).
There was a significant improvement in PFS with RIST among patients with MYCN-amplified disease (HR, 0.45; 95% CI, 0.24-0.84; P =.012), but there was no PFS improvement in patients without MYCN amplification (HR, 0.84; 95% CI, 0.51-1.38; P =.492).
In the entire study cohort, the median OS was 20 months in the RIST arm and 16 months in the control arm, a difference that did not reach statistical significance (HR, 0.68; 95% CI, 0.45-1.04; P =.073).
However, OS was significantly improved with RIST in the MYCN-amplified subgroup (HR, 0.51; 95% CI, 0.27-0.96; P =.037). OS was not improved with RIST in patients without MYCN amplification (HR, 0.91; 95% CI, 0.53-1.57; P =.731).
The safety population included 67 patients in the RIST arm and 60 patients in the control arm. Grade 3 or higher toxicities were reported for 97% of the RIST arm and 100% of the control arm.
Patients in the RIST arm had lower rates of grade 3 or higher anemia (58.2% and 63.3%, respectively) and infections (17.9% vs 21.7%) but a higher rate of grade 3 or higher neutropenia (88.1% vs 80.0%).
Dr Corbacioglu noted that RIST was safe and well tolerated, in addition to improving PFS in the overall population and OS in MYCN-amplified patients. RIST is easily accessible, can be given on an outpatient basis, and has oral and IV formulations available, he added.
Disclosures: Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of disclosures.
ReferenceCorbacioglu S, Lode HN, Jakob M, et al. Irinotecan and temozolomide combined with dasatinib and rapamycin for patients with relapsed or refractory neuroblastoma: Results of the prospective randomized RIST trial. ASCO 2023. June 2-6, 2023. Abstract 10001.
Reference